Cardiff Oncology Ownership | Who Owns Cardiff Oncology?
Cardiff Oncology Ownership Summary
Cardiff Oncology is owned by 59.56% institutional investors, 5.64% insiders, and 34.81% retail investors. Commodore capital lp is the largest institutional shareholder, holding 11.49% of CRDF shares. iShares Russell 2000 ETF is the top mutual fund, with 2.34% of its assets in Cardiff Oncology shares.
CRDF Ownership Benchmark
| Type | Name | % Inst | % Insiders | % Retail |
|---|---|---|---|---|
| Stock | Cardiff Oncology | 59.56% | 5.64% | 34.81% |
| Sector | Healthcare Stocks | 57.39% | 9.93% | 32.68% |
| Industry | Biotech Stocks | 68.48% | 9.65% | 21.87% |
Institutional Shareholders
Top Institutional Shareholders by Total Shares
| Holder | Shares | % Holding | Value |
|---|---|---|---|
| Commodore capital lp | 5.38M | 11.49% | $23.37M |
| Blackrock funding, inc. /de | 2.84M | 6.06% | $12.33M |
| Blackrock | 2.63M | 5.88% | $5.84M |
| Pfizer | 2.41M | 5.15% | $10.47M |
| Vanguard group | 2.28M | 4.88% | $9.92M |
| Orbimed advisors | 1.54M | 3.28% | $6.68M |
| Adage capital partners gp | 1.29M | 2.76% | $5.61M |
| Geode capital management | 982.88K | 2.10% | $4.27M |
| Mai capital management | 916.59K | 1.96% | $3.98M |
| State street | 848.58K | 1.81% | $3.68M |
Top Institutional Shareholders by % of Total Assets
| Holder | Shares | % Assets | Value |
|---|---|---|---|
| Commodore capital lp | 5.38M | 1.71% | $23.37M |
| Pfizer | 2.41M | 0.40% | $10.47M |
| Caxton | 13.29K | 0.35% | $57.66K |
| Ikarian capital | 450.00K | 0.27% | $1.95M |
| Orbimed advisors | 1.54M | 0.14% | $6.68M |
| Gsa capital partners llp | 380.07K | 0.12% | $1.65M |
| Elkhorn partners limited partnership | 32.00K | 0.09% | $139.00K |
| Avestar capital | 140.47K | 0.05% | $609.63K |
| Findec wealth services | 16.00K | 0.05% | $69.44K |
| Laurion capital management lp | 576.92K | 0.05% | $2.50M |
Top Buyers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Commodore capital lp | 5.38M | 1.71% | 5.38M |
| Pfizer | 2.41M | 0.40% | 2.41M |
| Blackrock | 2.63M | 0.00% | 1.95M |
| Orbimed advisors | 1.54M | 0.14% | 1.54M |
| Adage capital partners gp | 1.29M | 0.01% | 1.29M |
Top Sellers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Two sigma advisers, lp | 14.80K | 0.00% | -316.40K |
| Assenagon asset management | 67.23K | 0.00% | -203.29K |
| Eam investors | - | - | -161.90K |
| Ubs oconnor | - | - | -150.00K |
| Renaissance | 483.09K | 0.00% | -119.29K |
New Positions
| Holder | Shares | % Assets | Change | Value |
|---|---|---|---|---|
| Commodore capital lp | 5.38M | 1.71% | 5.38M | $23.37M |
| Pfizer | 2.41M | 0.40% | 2.41M | $10.47M |
| Orbimed advisors | 1.54M | 0.14% | 1.54M | $6.68M |
| Adage capital partners gp | 1.29M | 0.01% | 1.29M | $5.61M |
| Laurion capital management lp | 576.92K | 0.05% | 576.92K | $2.50M |
Sold Out
| Holder | Change |
|---|---|
| Newbridge financial services group | -17.00 |
| Macquarie group | -1.37K |
| America first investment advisors | -4.00K |
| Connor, clark & lunn investment management | -10.11K |
| Point72 (difc) | -12.28K |
Institutional Ownership Trends
| Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| Dec 31, 2024 | 121 | 35.96% | 27,910,732 | 118.71% | 59 | 8.03% | 73 | 114.71% | 15 | -37.50% |
| Sep 30, 2024 | 88 | -8.33% | 12,508,364 | -2.23% | 26 | 3.25% | 34 | -45.16% | 23 | 109.09% |
| Jun 30, 2024 | 96 | 17.07% | 12,794,219 | 52.97% | 28 | 8.17% | 62 | 40.91% | 11 | - |
| Mar 31, 2024 | 82 | 41.38% | 8,363,780 | 57.97% | 18 | 13.33% | 44 | 214.29% | 11 | -21.43% |
| Dec 31, 2023 | 58 | -3.33% | 5,294,425 | -2.97% | 11 | 7.95% | 14 | -26.32% | 14 | - |
Top Mutual Funds Shareholders
| Holder | Shares | % Holding | Change |
|---|---|---|---|
| iShares Russell 2000 ETF | 1.56M | 2.34% | 33.87K |
| Vanguard Total Stock Mkt Idx Inv | 1.52M | 2.29% | - |
| Vanguard US Total Market Shares ETF | 1.25M | 1.89% | - |
| CREF Stock R3 | 1.25M | 1.87% | 17.50K |
| CREF Stock R1 | 1.23M | 1.85% | 695.68K |
| Vanguard Institutional Extnd Mkt Idx Tr | 696.57K | 1.05% | 24.04K |
| Fidelity Small Cap Index | 400.87K | 0.60% | -7.51K |
| iShares Russell 2000 Value ETF | 328.92K | 0.49% | - |
| Fidelity Extended Market Index | 256.07K | 0.38% | -1.63K |
| BIT Biotech Opportunities S | 253.09K | 0.38% | - |
Recent Insider Transactions
| Date | Name | Role | Activity | Value |
|---|---|---|---|---|
| Dec 16, 2024 | Levine James E. | Chief Financial Officer | Buy | $9.82K |
| Dec 17, 2024 | Levine James E. | Chief Financial Officer | Buy | $14.91K |
| Dec 18, 2024 | Levine James E. | Chief Financial Officer | Buy | $12.00K |
| Dec 12, 2024 | TANNENBAUM RENEE P | - | Buy | $34.22K |
| Dec 11, 2024 | PACE GARY W | - | Buy | $29.90K |
Insider Transactions Trends
| Date | Buy | Sell |
|---|---|---|
| 2025 Q1 | - | - |
| 2024 Q4 | 6 | - |
| 2024 Q2 | - | - |
| 2024 Q1 | - | - |
| 2023 Q4 | 2 | - |
CRDF Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools